Last updated 18 days ago

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

698 patients around the world
Available in Argentina, Chile, Mexico, United States, Brazil, Spain
AbbVie
13Research sites
698Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
25 de mayo 174, Viedma, Río Negro
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Av. Galvan 4102, CABA, Buenos Aires
Hospital Británico de Buenos Aires - CABA
Hospital Británico de Buenos Aires - CABA
Recruiting
Perdriel 74, CABA, Buenos Aires
Centro Médico Austral OMI - CABA
Recruiting
Montevideo 955, C1019ABS Cdad. Autónoma de Buenos Aires, Argentina
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Juncal 2222, C1125 CABA, Argentina
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Av. San Martín 5481, CABA, Buenos Aires
Hospital de Câncer de Barretos - Fundação PIO XII
Recruiting
Rua Antenor Duarte Villela 1331 - Barretos, Sao Paulo, 14784-400
Instituto de Ensino e Pesquisa São Lucas
Recruiting
São Paulo, Sao Paulo, 01236-030
Instituto D'or de Pesquisa e Ensino - Rio de Janeiro
Recruiting
Rio de Janeiro, 22281-100
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Recruiting
Pr. da Cruz Vermelha, 23 - Centro, Rio de Janeiro - RJ, 20230-130
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy